Edition:
United States

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

17.00CHF
20 Aug 2018
Change (% chg)

CHF0.02 (+0.12%)
Prev Close
CHF16.98
Open
CHF17.00
Day's High
CHF17.00
Day's Low
CHF17.00
Volume
0
Avg. Vol
11,846
52-wk High
CHF74.00
52-wk Low
CHF15.90

Select another date:

Fri, Jun 22 2018

BRIEF-Santhera: MHRA Renews Early Access Option For Raxone For Duchenne

* UK'S MHRA RENEWS EARLY ACCESS TO MEDICINES SCHEME SCIENTIFIC OPINION FOR SANTHERA'S RAXONE® (IDEBENONE) IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Santhera Successfully Completes First Clinical Trial With Omigapil In Patients With Congenital Muscular Dystrophy ‍​

* SUCCESSFUL COMPLETION OF FIRST CLINICAL TRIAL WITH OMIGAPIL IN PATIENTS WITH CONGENITAL MUSCULAR DYSTROPHY ‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Santhera Pharmaceuticals FY ‍Net Result At CHF -51.5 Mln

* SANTHERA PHARMACEUTICALS - FY ‍NET REVENUES FROM SALES OF LEAD PRODUCT RAXONE® INCREASED BY 21% TO CHF 22.9 MILLION​

Santhera's Raxone shows no efficacy benefit in MS study

ZURICH Santhera Pharmaceuticals said on Monday a study of its medicine Raxone in primary progressive multiple sclerosis showed no difference between the treatment and placebo groups in disease progression, another setback for the Swiss drug company.

BRIEF-Santhera Pharmaceuticals ‍Reports Outcome Of Exploratory Trial With Idebenone In PPMS Conducted At NIH​

* ‍REPORTS OUTCOME OF EXPLORATORY TRIAL WITH IDEBENONE IN PPMS CONDUCTED AT NIH​

BRIEF-Santhera Completes Capital Increase To Settle Obtained License From Polyphor

* SANTHERA COMPLETES CAPITAL INCREASE TO SETTLE OBTAINED LICENSE FROM POLYPHOR

Select another date: